FECH and prostate cancer: Correspondingly, the inhibition of FECH has been previously shown to enhance 5‐ALA‐PDT in PC3 prostate cancer,45 while genetically silencing FECH has been proved to synergize with 5‐ALA‐PDT on the glioma cells SNB19.6